The significance of single nucleotide polymorphism rs2070770 in CD20 gene in Chinese patients with diffuse large B-cell lymphoma

References

• Nadler LM, Ritz J, Hardy R, et al. A unique cell surface antigen identifying lymphoid malignancies of B cell origin. J Clin Invest 1981;67:134–140.
   PubMed Web of Science ®Google Scholar
• Stashenko P, Nadler LM, Hardy R, et al. Expression of cell surface markers after human B lymphocyte activation. Proc Natl Acad Sci USA 1981;78:3848–3852.
   PubMed Web of Science ®Google Scholar
• Anderson KC, Bates MP, Slaughenhoupt BL, et al. Expression of human B cell-associated antigens on leukemias and lymphomas:a model of human B cell differentiation. Blood 1984;63:1424–1433.
   PubMed Web of Science ®Google Scholar
• Beers SA, Chan CH, French RR, et al. CD20 as a target for therapeutic type I and II monoclonal antibodies. Semin Hematol 2010;47:107–114.
   PubMed Web of Science ®Google Scholar
• Cragg MS, Walshe CA, Ivanov AO, et al. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 2005;8:140–174.
   PubMedGoogle Scholar
• Kanzaki M, Lindorfer MA, Garrison JC, et al. Activation of the calcium-permeable cation channel CD20 by alpha subunits of the Gi protein. J Biol Chem 1997;272:14733–14739.
   Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC Press; 2008.
   Google Scholar
• Brusamolino E. First-line therapy of CD20 + diffuse large B-cell lymphoma: facts and open questions. Haematologica 2009;94: 1194–1198.
   PubMed Web of Science ®Google Scholar
• Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121–3127.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trümper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379–391.
   PubMed Web of Science ®Google Scholar
• Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 2005;23:4117–4126.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005;23:5027–5033.
   PubMed Web of Science ®Google Scholar
• Gordan LN, Grow WB, Pusateri A, et al. Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. J Clin Oncol 2005;23:1096–1102.
   PubMed Web of Science ®Google Scholar
• Johnson NA, Boyle M, Bashashati A, et al. Diffuse large B-cell lymphoma:reduced CD20 expression is associated with an inferior survival. Blood 2009;113:3773–3780.
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Yoshida T, Wang G, et al. Association of CD20 levels with clinicopathological parameters and its prognostic significance for patients with DLBCL. Ann Hematol 2012;91:997–1005.
   PubMed Web of Science ®Google Scholar
• Sar A, Perizzolo M, Stewart D, et al. Mutation or polymorphism of the CD20 gene is not associated with the response to R-CHOP in diffuse large B cell lymphoma patients. Leuk Res 2009;33:792–797.
   Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103:275–282.
   PubMed Web of Science ®Google Scholar
• The International Non-Hodgkin's Lymphoma Prognostic Factors. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 1993;329:987–994.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Johnson NA, Leach S, Woolcock B, et al. CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure. Haematologica 2009;94:423–427.
   Google Scholar
• Binder M, Otto F, Mertelsmann R, et al. The epitope recognized by rituximab. Blood 2006;108:1975–1978.
   PubMed Web of Science ®Google Scholar
• Du J, Wang H, Zhong C, et al. Structural basis for recognition of CD20 by therapeutic antibody Rituximab. J Biol Chem 2007;282: 15073–15080.
   PubMed Web of Science ®Google Scholar